

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: tba
Filed: tba
1st Inventor: Hiroyuki Odaka
For: Agent for Improving Acidosis
Atty. Dkt. No. 2596 US1P

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Information Disclosure Statement

MAIL STOP PATENT APPLICATION
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference has been made available in the prior pending application Serial No. 09/937,447, filed September 26, 2001.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: 11/20/03

(847) 383-3391
(847) 383-3372

Elaine M. Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

FORM PTO 1449 (modified)		ATTY DOCKET NO.: 2596 US1P		SERIAL NO.: tba			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)							
Date Submitted to PTO:				APPLICANT: H. Odaka			
				FILING DATE: tba	GROUP: tba		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		2002/0042441	4/11/2002	J. Acton III, et al.			
		6,329,403	12/11/2001	H. Odaka, et al.			
		6,251,926	6/26/2001	Y. Momose, et al.			
		5,965,589	10/12/1999	T. Sohda, et al.			
		5,932,601	8/3/1999	T. Sohda, et al.			
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		WO 98/57634	23 DEC 1998	WO			
		EP 0 749 751 A2	27 DEC 1996	EP			
		WO 97/37656	16 OCT 1997	WO			
OTHER DOCUMENT(S)							
*EXAMINER INITIAL	REF No.	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.					
		Inoue, I et al. "Effect of Troglitazone (CS-045) and benzafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats." Metabolism Clinical and Experimental Vol. 44(12):1626-1630 (1995)					
		Kemnitz, J. et al. "Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels and lowers blood pressure in obese, insulin-resistant rhesus monkeys." Diabetes Vol. 43(2):204-211 (1994)					
		Fujiwara, T. "Characterization of new oral antidiabetic agent CS-045 studies in KK and OB-OB mice and Zucker fatty rats." Diabetes Vol. 37(11):1549-1558 (1988)					
		Murakami, K. et al. "A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma. Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats." Diabetes Vol. 47(12):1841-1847 (1998)					
		Oakes, N. et al. "A new antidiabetic agent BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat." Diabetes Vol. 43(10):1203-1210 (1994)					
		Bowen, L. et al. "The effect of CP-68722 A Thiazolidinedione derivative on insulin sensitivity in lean and obese Zucker rats." Metabolism Clinical and Experimental Vol. 40(10):1025-1030 (1991)					
		Windholz, et al. THE MERCK INDEX, Tenth Edition (1983) pages 723 and 724, Abstract No. 4866.					
EXAMINER:				DATE CONSIDERED:			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.